SecBot SecBot
8-K ·Filed Mar 11, 2026

PLRX

PLIANT THERAPEUTICS, INC.
BULLISH
Impact 7/10
Horizonmonths Processed8mo ago SEC0001746473-26-000039
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Phase 1 data and accelerated development of PLN-101095 represent a significant value inflection point. The extended cash runway reduces near-term dilution risk. Traders should monitor upcoming interim data from the Phase 1b trial in 2027 as a key catalyst.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.41
T+0 close · Mar 11, 2026 · via day close
Latest settled
−18.44%
T+60 · $1.15
Vs SPY
−29.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 12 $1.41entry
  2. T+1 · 8mo ago −4.26%α −3.66% · $1.35
  3. T+5 · 8mo ago −5.67%α −4.70% · $1.33
  4. T+20 · 7mo ago −9.22%α −11.19% · $1.28
  5. T+60 · 5mo ago −18.44%α −29.14% · $1.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pliant Therapeutics reported fourth quarter 2025 financial results and provided a corporate update, highlighting positive Phase 1 data for its oncology drug PLN-101095 in checkpoint inhibitor-refractory solid tumors. The company initiated a Phase 1b indication expansion trial and reported reduced R&D and G&A expenses, leading to a narrower net loss. It has $192.4 million in cash, sufficient to fund operations into the second half of 2028.

Key Financial Metrics

EPS
$-0.38

Key Facts

  • PLN-101095 showed deep and durable responses in ICI-refractory patients, with 4 responders (1 complete, 3 partial) out of 10 patients across multiple tumor types.
  • Phase 1b indication expansion trial initiated in NSCLC, renal cell carcinoma, and high tumor mutational burden tumors, with first patient enrollment expected in Q2 2026 and interim data in 2027.
  • Q4 2025 R&D expenses decreased to $15.6M from $38.8M YoY due to discontinuation of BEACON-IPF.
  • Q4 2025 G&A expenses decreased to $8.0M from $14.5M YoY due to workforce restructuring.
  • Net loss narrowed to $23.6M from $49.7M YoY.
  • Cash, cash equivalents, and short-term investments totaled $192.4M as of December 31, 2025, expected to fund operations into H2 2028.

Financial Impact

R&D expenses down 60% YoY, G&A down 45% YoY, net loss down 52.5% YoY, with cash runway extending into 2028.

research and development expensesgeneral and administrative expensesnet losscash runway

Risk Factors

  • Clinical development risk: PLN-101095 is still in early stages; future trial results may not replicate initial success.
  • Dilution risk: Despite current cash runway, future financing may be required for later-stage trials, potentially diluting shareholders.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001746473-26-000039
Document: plrx-20260311.htm0001746473-26-000039
Document: 0001746473-26-000039-index-headers.html0001746473-26-000039
Document: 0001746473-26-000039-index.html0001746473-26-000039
Document: 0001746473-26-000039.txt0001746473-26-000039

Track record

8 reports on PLRX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6970 Now $0.6930 −0.57% settles Feb 11
  2. Aug 18, 202612w ago Press Release Bullish 4/10 Entry $1.15 to $0.7857 Now $0.6930 −39.74% ▼ −31.68% −29.64% vs SPY
  3. May 11, 202627w ago 8-K Neutral 4/10 No price data
  4. May 11, 202627w ago Press Release Bearish 6/10 Entry $1.18 to $1.05 Now $0.6930 +41.27% ▲ +11.02% +15.40% vs SPY
  5. Apr 17, 202630w ago 8-K Mixed 6/10 Entry $1.29 to $1.12 Now $0.6930 −46.28% ▼ −13.18% −19.96% vs SPY
  6. Apr 7, 202632w ago EFFECT Neutral 4/10 Entry $1.31 to $1.17 Now $0.6930 −47.10% ▼ −10.69% −23.96% vs SPY
  7. Mar 11, 202635w ago 8-K Bullish 7/10 Viewing Entry $1.41 to $1.15 Now $0.6930 −50.85% ▼ −18.44% −29.14% vs SPY
  8. Mar 3, 202636w ago 8-K Neutral 3/10 Entry $1.29 to $1.25 Now $0.6930 −46.28% ▼ −3.10% −13.19% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 11, 2026